Xilio Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $18.70M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $12.60M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | $13.70M | $0.81 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $19.10M | $-0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $8.10M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $2.90M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | $1.70M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $2.30M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Xilio Therapeutics filed with the SEC
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pricing of Underwritten Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40 th Annual Meeting
Regulation FD disclosure · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Unleashing the Potential of Immuno-Oncology Therapies May 31, 2025 © 2025 Xilio Therapeutics, Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
© 2025 Xilio Therapeutics, Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
© 2024 Xilio Therapeutics, Inc.
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2024 Xilio Therapeutics, Inc.
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Gilead and Xilio Announce Exclusive License Agreement
Material agreement · Results of operations · Exit or restructuring costs · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Material agreement · Results of operations · Exit or restructuring costs · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2023 Xilio Therapeutics, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
© 2023 Xilio Therapeutics, Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K